Moreover, considering c-MYC as one of the miRNA-126*-predicted targets, the NSD2-dependent inhibition of miRNA-126* could result in increased c-MYC expression, thus contributing to MM pathogenesis [53]. This evidence concerns the gene NSD2 and Miyoshi myopathy.